Johnson & Johnson at Morgan Stanley Healthcare Conference Transcript
Let's go ahead and get going here. My name is David Lewis, medical device analyst from Morgan Stanley. It's my pleasure to have us here several members of J&J both on the stage with me and in the audience. To my immediate left, obviously, Scott White, who's group company's Chairman, North American Pharmaceuticals; and Peter Lebowitz, who's Global Therapeutic Head of Oncology. And we've been to the MDA or the Pharmaceutical Day for Johnson & Johnson. You've seen Peter here the last several years.
But before we get going, we're going to have a statement read by Lesley in the audience on J&J public safe harbor, and then we'll get going.
Great. Thanks, David. Good morning, everyone. Please note that some statements made today may be considered forward-looking or utilize non-GAAP measures. Please refer to our SEC filings, in particular our 10-K, which discuss the risks and uncertainties around forward-looking statements as well
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |